Civil money penalties
This article was originally published in The Gray Sheet
FDA is extending to Aug. 25 the comment period on its proposed rule "to establish hearing procedures when a hearing is requested concerning" the imposition of civil money penalties for medical devices, drugs and biologics, according to a July 27 Federal Register announcement.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.